image
Pro-Dex, Inc. PDEX
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
Watchlist
$ 40.54
-0.735 %
$ 132 M
Market Cap
14.69
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one PDEX stock under the worst case scenario is HIDDEN Compared to the current market price of 40.5 USD, Pro-Dex, Inc. is HIDDEN

PDEX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one PDEX stock under the base case scenario is HIDDEN Compared to the current market price of 40.5 USD, Pro-Dex, Inc. is HIDDEN

PDEX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one PDEX stock under the best case scenario is HIDDEN Compared to the current market price of 40.5 USD, Pro-Dex, Inc. is HIDDEN

PDEX Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart PDEX

image
1M 0%
6M -19%
1Y 106%
3Y 154%
5Y 127%
All
$70.0$70.0$65.0$65.0$60.0$60.0$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
53.8 M REVENUE
16.83%
Growth Rates
1Year 16.83%
3Years 12.29%
5Years 14.66%
7Years 13.68%
10Years 17.41%
7.17 M OPERATING INCOME
24.49%
Growth Rates
1Year 24.49%
3Years 16.60%
5Years 7.49%
7Years 14.77%
10Years 26.88%
2.13 M NET INCOME
-69.93%
Growth Rates
1Year -69.93%
3Years -21.81%
5Years -12.50%
7Years -11.70%
10Years 20.32%
6.2 M OPERATING CASH FLOW
13.49%
Growth Rates
1Year 13.49%
3Years 70.81%
5Years 13.26%
7Years 9.74%
10Years 35.49%
-2.23 M INVESTING CASH FLOW
-152.32%
Growth Rates
1Year -152.32%
3Years 15.57%
5Years -12.81%
7Years -11.75%
10Years -22.98%
-4.27 M FINANCING CASH FLOW
-71.53%
Growth Rates
1Year -71.53%
3Years -33.57%
5Years -60.02%
7Years -46.28%
10Years -14.35%
17.4 M REVENUE
3.70%
Growth Rates
1Year 16.83%
3Years 12.29%
5Years 14.66%
7Years 13.68%
10Years 17.41%
3.64 M OPERATING INCOME
35.22%
Growth Rates
1Year 24.49%
3Years 16.60%
5Years 7.49%
7Years 14.77%
10Years 26.88%
3.28 M NET INCOME
60.54%
Growth Rates
1Year -69.93%
3Years -21.81%
5Years -12.50%
7Years -11.70%
10Years 20.32%
754 K OPERATING CASH FLOW
118.17%
Growth Rates
1Year 13.49%
3Years 70.81%
5Years 13.26%
7Years 9.74%
10Years 35.49%
1.73 M INVESTING CASH FLOW
418.63%
Growth Rates
1Year -152.32%
3Years 15.57%
5Years -12.81%
7Years -11.75%
10Years -22.98%
1.93 M FINANCING CASH FLOW
14.85%
Growth Rates
1Year -71.53%
3Years -33.57%
5Years -60.02%
7Years -46.28%
10Years -14.35%
Balance Sheet Pro-Dex, Inc.
image
Current Assets 36.6 M
Cash & Short-Term Investments 6.85 M
Receivables 13.9 M
Other Current Assets 15.9 M
Non-Current Assets 15.9 M
Long-Term Investments 1.56 M
PP&E 12.7 M
Other Non-Current Assets 1.65 M
13.05 %26.46 %30.25 %2.98 %24.11 %3.15 %Total Assets$52.5m
Current Liabilities 12.9 M
Accounts Payable 4.51 M
Short-Term Debt 4.83 M
Other Current Liabilities 3.55 M
Non-Current Liabilities 8.72 M
Long-Term Debt 8.72 M
Other Non-Current Liabilities 0
20.88 %22.35 %16.43 %40.34 %Total Liabilities$21.6m
EFFICIENCY
Earnings Waterfall Pro-Dex, Inc.
image
Revenue 53.8 M
Cost Of Revenue 39.3 M
Gross Profit 14.6 M
Operating Expenses 7.38 M
Operating Income 7.17 M
Other Expenses 5.05 M
Net Income 2.13 M
60m60m50m50m40m40m30m30m20m20m10m10m0054m(39m)15m(7m)7m(5m)2mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
27.02% GROSS MARGIN
27.02%
Averages
1Year 27.02%
3Years 28.64%
5Years 31.87%
7Years 32.96%
10Years 31.79%
13.32% OPERATING MARGIN
13.32%
Averages
1Year 13.32%
3Years 12.67%
5Years 14.04%
7Years 14.18%
10Years 10.76%
3.95% NET MARGIN
3.95%
Averages
1Year 3.95%
3Years 10.06%
5Years 11.88%
7Years 11.70%
10Years 10.64%
6.89% ROE
6.89%
Averages
1Year 6.89%
3Years 16.20%
5Years 20.56%
7Years 19.51%
10Years 17.86%
4.05% ROA
4.05%
Averages
1Year 4.05%
3Years 9.12%
5Years 11.61%
7Years 11.78%
10Years 11.80%
13.04% ROIC
13.04%
Averages
1Year 13.04%
3Years 10.94%
5Years 12.61%
7Years 12.71%
10Years 12.02%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Pro-Dex, Inc.
image
6m6m4m4m2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 2.13 M
Depreciation & Amortization 1.16 M
Capital Expenditures -983 K
Stock-Based Compensation 605 K
Change in Working Capital -225 K
Others 4.47 M
Free Cash Flow 5.22 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Pro-Dex, Inc.
image
PDEX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Pro-Dex, Inc.
image
Sold
0-3 MONTHS
405 K USD 2
3-6 MONTHS
3.77 M USD 1
6-9 MONTHS
40 K USD 1
9-12 MONTHS
47.3 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Here is Why Growth Investors Should Buy ProDex (PDEX) Now ProDex (PDEX) is well positioned to outperform the market, as it exhibits above-average growth in financials. zacks.com - 1 week ago
ProDex (PDEX) Upgraded to Buy: Here's Why ProDex (PDEX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 1 week ago
Pro-Dex: Crash After Strong Earnings Leads To A Buying Opportunity Pro-Dex, Inc. experienced a 32% stock crash despite record Q3 2025 performance, presenting a buying opportunity for risk-tolerant investors. Q3 2025 revenue grew 22% YoY, with gross profit up 45% due to favorable product mix; operating income increased 64%. PDEX's PEG ratio of 0.27x indicates undervaluation compared to sector median, despite higher valuation multiples in other metrics. seekingalpha.com - 1 month ago
Pro-Dex, Inc. (PDEX) Q3 Earnings Surpass Estimates Pro-Dex, Inc. (PDEX) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.19 per share a year ago. zacks.com - 1 month ago
ProDex (PDEX) Moves 5.1% Higher: Will This Strength Last? ProDex (PDEX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com - 2 months ago
Take the Zacks Approach to Beat the Markets: Pro-Dex, Brookdale Senior Living, Coca-Cola in Focus Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months. zacks.com - 2 months ago
ProDex (PDEX) Surges 7.4%: Is This an Indication of Further Gains? ProDex (PDEX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com - 2 months ago
ProDex (PDEX) Upgraded to Strong Buy: Here's What You Should Know ProDex (PDEX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 3 months ago
Q4 2024 Portfolio Update: Growth Has Come Patiently In 4Q24, we crossed $10M in AUM, emphasizing patient growth and strategic portfolio management, with a focus on long-term investments and five-year doubles. Key drivers include CCRD, PDEX, and RSSS, with CoreCard benefiting from a new contract with Goldman, and Pro-Dex showing strong business performance. Matrix Service is expected to convert backlog to profit in the next 18-24 months, while new positions are anticipated to start small. seekingalpha.com - 4 months ago
Pro-Dex, Inc. (PDEX) Surpasses Q2 Earnings and Revenue Estimates Pro-Dex, Inc. (PDEX) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.14 per share a year ago. zacks.com - 4 months ago
Pro-Dex, Inc. Announces Fiscal 2025 Second Quarter and Six-Month Results IRVINE, CA / ACCESS Newswire / January 30, 2025 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2025 second quarter ended December 31, 2024. accessnewswire.com - 4 months ago
All You Need to Know About ProDex (PDEX) Rating Upgrade to Buy ProDex (PDEX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 4 months ago
8. Profile Summary

Pro-Dex, Inc. PDEX

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 132 M
Dividend Yield 0.00%
Description Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.
Contact 2361 McGaw Avenue, Irvine, CA, 92614 https://www.pro-dex.com
IPO Date Aug. 7, 1986
Employees 146
Officers Mr. Chris Jackson Directors of Operations Ms. Alisha K. Charlton Chief Financial Officer & Corporate Secretary Mr. Richard Lee Van Kirk Jr. Chief Executive Officer, President & Director